Accordingly, late-stage CTCL is characterized by a Th2-dominated tumor microenvironment and a paucity of benign Th1 cells and CD8+ T cells [32–34, 37–39, 41]. This evidence concerns the gene CD8A and primary cutaneous T-cell non-Hodgkin lymphoma.